Collegium is engaged in developing and commercializing abuse-deterrent products incorporating its patented DETERx platform technology, designed to maintain extended-release and safety profiles in the face of various abuse methods. Disciplined acquisitions and targeted investments in ADHD therapies diversify the portfolio and reduce risk, supporting stable long-term earnings.
Cyborg Score Rationale
With a market cap of $1.46B and trailing twelve-month revenue of $757M, Collegium demonstrates solid financial scale. The company delivered earnings and revenue surprises of +19.68% and +10.35% for Q3 2025. However, the company faces looming generic competition for Nucynta and growing policy pressure on U.S. drug pricing and reimbursement.
Top Insights
Collegium generated record quarterly net revenue of $188.0 million in Q2 2025, up 29% year-over-year, with Jornay PM net revenue of $32.6 million growing 23% YoY.
As of January 31, 2026, there were 31,753,211 common shares outstanding with aggregate market value of approximately $926.4 million.
The Board authorized a new $150 million share repurchase program through December 31, 2026, reflecting management's commitment to returning value to shareholders.
The company operates in a heavily regulated environment with extensive opioid and stimulant regulation, REMS obligations, and patent/exclusivity timing pressures.
Named Competitors
Pain Management Portfolio — Regional anesthetic and pain management solutions
ADHD Treatments — Neuropsychiatric and ADHD therapies
Opioid Alternatives — Gastrointestinal and opioid-related treatments